The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sells continue and across market . yet BSFA purchasers still filling up .Real meat any day .
Can it be a back ground seller .
Bank of America...£145 ? That would be good, er, when? Even so, eventually would still be good. Gotta have fun haven't we. Happy Christmas
Interesting..but no financial information.
With some sites offering part shares a share split is irrelevant.
Why would the company want a lot of small shareholders on its list? More cost, no gain….
Warren Buffet has done ok with Berkshire Hathaway shares over $100k
buy twice as many perhaps?
why bother?
Small shareholders would surely benefit from a share split. The price is out of line with much of the FT100. 10 for 1 perhaps?
citi liking it too, 14000 target.
if only these broker upgrades
ever meant anything, *sigh*.
five year graph looking rather nice these days.
Two nice upgrades reported today.
While Pharma will be an easy target for pressure to cut prices paid for by public funds, politicians need to be careful what they legislate for. The companies are good at finding ways to exploit loopholes and there could be supply issues if the price is too low.
From Endpoints
AstraZeneca and Merck executives are now raising concerns about how the IRA will impact cancer drug development moving forward as the clock for negotiations begins with the first approved indication.
On an investor call yesterday (this week), AstraZeneca CEO Pascal Soriot said that his company may no longer launch new cancer drugs in the US unless it’s for a large enough indication to keep that clock from starting too soon.
“There is a disincentive to start with small indications,” Soriot said on the call, adding:
That’s mostly true for oncology, where if you have to start with a third-line indication, patients would benefit from this, but we may not do it in the future or not launch in the U.S. We may launch elsewhere in the world, but not launch in the U.S. until we have approval for a larger indication, because the clock starts as soon as you get approval. So, that’s that. Those are really negative factors that are real problems with this.
Or?…....
https://www.biopharmadive.com/news/pharma-drug-pricing-ira-law-impact-negotiation/636110/
? some of the fall today perhaps a negative read-across
re PARP class inhibitorsfrom the GSK news re zeluja?
couple of snippets re AZN & covid, for interest re broader s/p context:
https://www.bmj.com/content/379/bmj.o2592
https://www.fiercepharma.com/pharma/astrazeneca-weighs-spinning-division-covid-19-vaccine-antibodies-into-separate-company
A strong dollar is a headwind not a tailwind, check out table 17 in the Results RNS
Another buying opportunity...
it’s result of strong pound and weaker dollar taking effect. that’s quite obvious to most.. risk on risk off effect
Strange to see the share price fall today on the back of ye another cancer drug achieving FDA approcal and the strengthening of the pound v dollar on the back of US CPI data better than expected, which will of course reduce FX headwind impact on future profits
Roperace - I'm on my pension now, hope they are paying it for many years. I wish you good health and wealth :-)
Likewise SYN00GOLD - since 1996.
Quality research and disciplined capital allocation is paying off in rising sales and will feed into dividends.
Although I dare say the politicians will be thinking about ways to tax the companies and shareholders more….although that will result in higher drug charges…and patient detriment.
Good set of results and nice for my long term fund. As an ex employee, been collecting shares since 1992 when Zeneca :-)
Hold and enjoy. Many a nice holiday courtesy of AZ over the years. Thanks Pascal and Tom McKillop !!